Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKC-E2 is a topical cosmetic cream developed by CK Cell Technologies Pty Ltd, formulated with conditioned media derived from human umbilical cord mesenchymal stem cells (hUC-MSCs). The product is designed to address signs of facial skin ageing, such as reduced hydration, loss of elasticity, and increased roughness. The mechanism of action involves the delivery of a complex secretome—comprising growth factors, cytokines, and extracellular vesicles (exosomes)—that stimulates dermal fibroblasts and promotes the synthesis of extracellular matrix components like collagen and elastin. CKC-E2 has been evaluated in randomized, double-blind, split-face pilot clinical trials to assess its efficacy and safety compared to placebo and the related formulation CKC-E1 in healthy adult women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CKC-E2.